---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-026807"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2023-06-07T23:59:59+00:00"
generated_at: "2026-06-14T05:52:27.239312+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Reneo shareholders elect three Class III directors, ratify auditor at 2023 annual meeting

## Summary
- Elected all three Class III director nominees: Mathers 15.75M for, Muralidhar 15.42M for, Seltzer 15.94M for; 3.76M broker non-votes each.
- Ratified Ernst & Young as independent auditor for FY2023 with 20.32M votes for, 12.6K against, 100 abstain.
- Record date April 10, 2023; 25,107,430 shares outstanding entitled to vote.

## SEC filing metadata
- accession: 0000950170-23-026807
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2023-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017023026807/0000950170-23-026807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017023026807/rphm-20230606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-026807
- JSON: https://secwatch.observer/filing/0000950170-23-026807.json
- Plain text: https://secwatch.observer/filing/0000950170-23-026807.txt

## Key facts
- Shareholder Votes
  OnKure Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-06 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: For Against Abstain Broker Non-Votes 20,316,020 12,633 100 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000095017023026807/0000950170-23-026807-index.htm
- Shareholder Votes
  OnKure Therapeutics, Inc. shareholders approved Election of Directors at the 2023-06-06 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class III directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: For Abstain Broker Non-Votes Edward T. Mathers 15,749,259 815,951 3,763,543 Bali Muralidhar, M.D., Ph.D. 15,423,901 1,141,309 3,763,543 Stacey D. Seltzer 15,937,901 627,309 3,763,543
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000095017023026807/0000950170-23-026807-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.